Plethora Solutions Holdings PLC completed a tightly choreographed, three-way transaction Tuesday, involving a share issue that grossed £18.2 million (US$29.5 million), the buyback of all outstanding rights to its premature ejaculation drug PSD502, and the licensing of rights to the same drug in Europe and neighboring territories to Recordati SpA in a deal worth up to €46 million (US$59.5 million) in up-front and milestone payments, plus royalties.